Raymond James Upgrades Allogene Therapeutics to Outperform, Announces $36 Price Target

Raymond James analyst Dane Leone upgrades Allogene Therapeutics (NASDAQ:ALLO) from Market Perform to Outperform and announces $36 price target.

byBenzinga Newsdesk

September 24, 2021

1 minute read

Raymond James analyst Dane Leone upgrades Allogene Therapeutics (NASDAQ:ALLO) from Market Perform to Outperform and announces $36 price target.

HC Wainwright & Co. Maintains Buy on Ascendant Resources, Lowers Price Target to C$0.35

By Benzinga Newsdesk

Today, 10:54 PM

HC Wainwright & Co. analyst Heiko Ihle maintains Ascendant Resources (TSX:ASND) with a Buy and lowers the price target from C$0.4 to C$0.35.

TSX:ASND

Shiba Inu Set To Launch Beta Version Of Doggy DAO To Give Users More Power, Reduce Whale Influence

By Bibhu Pattnaik

Today, 10:54 PM

According to a new blog post, Shiba Inu (CRYPTO: SHIB) developers have launched a beta version of a decentralized autonomous organization (DAO) called Doggy.

$SHIB

Kewaunee Scientific Q1 EPS $(0.27) Up From $(0.48) YoY, Sales $50.12M Up From $39.49M YoY

By Michael Horton

Today, 10:54 PM

Kewaunee Scientific (NASDAQ:KEQU) reported quarterly losses of $(0.27) per share. This is a 43.75 percent increase over losses of $(0.48) per share from the same period last year. The company reported $50.12 million in

KEQU

EXCLUSIVE: Knightscope Projects Annualized Revenue To More Than Triple In 2022

By Anusuya Lahiri

Today, 10:54 PM

Knightscope, Inc (NASDAQ: KSCP), a developer of autonomous security robots, shared its anticipated revenue growth for the next twelve months and looked to broadcast the first video episode in a series titled “Rise of the Robots” today across its social media platforms.

KSCP

Raymond James Upgrades Allogene Therapeutics to Outperform, Announces $36 Price Target

Related Posts

HC Wainwright & Co. Maintains Buy on Ascendant Resources, Lowers Price Target to C$0.35

Shiba Inu Set To Launch Beta Version Of Doggy DAO To Give Users More Power, Reduce Whale Influence

Kewaunee Scientific Q1 EPS $(0.27) Up From $(0.48) YoY, Sales $50.12M Up From $39.49M YoY

EXCLUSIVE: Knightscope Projects Annualized Revenue To More Than Triple In 2022